New York Life Investment Management LLC Atea Pharmaceuticals, Inc. Transaction History

New York Life Investment Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$2.8 - $3.35 $8,943 - $10,699	-3,194 Reduced 3.01%	103,087 $314,000
Q3 2023 Nov 07, 2023	SELL	$3.0 - $3.79 $50,232 - $63,459	-16,744 Reduced 13.61%	106,281 $318,000
Q2 2023 Aug 04, 2023	SELL	$3.21 - $5.06 $71,692 - $113,010	-22,334 Reduced 15.36%	123,025 $460,000
Q1 2023 May 08, 2023	BUY	$3.0 - $4.97 $200,388 - $331,976	66,796 Added 85.02%	145,359 $486,000
Q4 2022 Feb 10, 2023	BUY	$4.35 - $6.17 $38,497 - $54,604	8,850 Added 12.69%	78,563 $377,000
Q3 2022 Nov 10, 2022	BUY	$5.49 - $8.79 $28,125 - $45,031	5,123 Added 7.93%	69,713 $397,000
Q2 2022 Aug 12, 2022	BUY	$5.33 - $8.18 $344,264 - $528,346	64,590 New	64,590 $459,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of New York Life Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on New York Life Investment Management LLC with notifications on news.